AbbVie Enhances Aesthetics with SKINVIVE for Neck Treatment and Acquires Capstan Therapeutics
- AbbVie’s Allergan Aesthetics launches SKINVIVE, the first injectable approved for neck line treatment in the U.S.
- Clinical studies show 80% of participants improved neck line severity after one month with SKINVIVE.
- AbbVie expands its aesthetic portfolio with SKINVIVE, reinforcing its commitment to comprehensive aesthetic solutions.
AbbVie Expands Aesthetic Offerings with SKINVIVE for Neck Treatment
AbbVie’s subsidiary, Allergan Aesthetics, introduces a significant advancement in aesthetic medicine with SKINVIVE by JUVÉDERM®, the only hyaluronic acid microdroplet injectable approved in the U.S. for enhancing cheek skin smoothness in adults over 21. A recent development sees the FDA accept Allergan's supplemental premarket approval (sPMA) application for SKINVIVE, aimed at expanding its indications to address neck lines. This potential expansion could mark the first injectable treatment specifically designed for this often-neglected area, providing a new solution for adults suffering from moderate to severe horizontal neck lines.
The clinical study supporting this application demonstrates promising results, with 80% of participants achieving at least a one-grade improvement in neck line severity after one month. Nearly 90% of patients report an enhanced neck appearance based on the Global Aesthetic Improvement Scale. Moreover, the FACE-Q questionnaire indicates significant reductions in dissatisfaction regarding neck aesthetics compared to a control group. The findings emphasize a growing concern among many individuals seeking effective treatments for neck issues, highlighting the potential for SKINVIVE to meet an increasing demand in the aesthetic market.
By broadening the indications for SKINVIVE, Allergan not only reinforces its dedication to comprehensive aesthetic solutions but also enhances its existing portfolio, which includes well-known products like BOTOX Cosmetic® and SkinMedica®. The expansion reflects a strategic move to cater to the evolving needs of consumers in the cosmetic sector, as millions consider professional interventions to improve their neck appearance. Upcoming presentations of further clinical data at medical congresses will likely solidify SKINVIVE's standing in the aesthetic treatment landscape.
In addition to this aesthetic breakthrough, AbbVie announces its definitive agreement to acquire Capstan Therapeutics, a company recognized for its innovative targeted lipid nanoparticle technology. This acquisition includes Capstan's promising anti-CD19 chimeric antigen receptor (CAR) therapy, currently in Phase 1 trials for B cell-mediated autoimmune diseases. AbbVie's focus on advancing immunology is further underscored by this strategic move, which aims to transform patient care by targeting the underlying mechanisms of autoimmune disorders.
The innovative approach of Capstan’s technology, which allows for in vivo CAR-T therapy without the need for complex ex vivo manufacturing processes, positions CPTX2309 as a potential game-changer in the treatment of autoimmune diseases. This reinforces AbbVie’s commitment to improving patient outcomes while expanding its capabilities in clinical development and commercialization.
